MARKET

INAI

INAI

Invea Therapeutics, Inc.
NASDAQ
--
0.00
0.00%
Opening
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
INVEA THERAPEUTICS INC SAYS IT HAD FILED FOR IPO IN DECEMBER 2025
Reuters · 03/06 21:08
About INAI
Invea Therapeutics Inc. is a biotechnology company, which is engaged in developing small molecule oral therapeutics for immune-mediated inflammatory diseases (IMIDs). The Company’s product candidates include INVA8001 and INVA8003. The Company’s lead product candidate, INVA8001, is an oral, small-molecule, highly selective, and potent chymase inhibitor designed to target mast cell-driven inflammation in immune-mediated inflammatory diseases. The Company’s second product candidate, INVA8003, is a novel oral small-molecule inhibitor of apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC), an adaptor protein that facilitates the assembly and activation of various inflammasomes, which are key mediators that drive inflammatory responses and cell death. Its product candidates are identified using the AlphaMeld Platform, a technology-enabled drug discovery platform.

Webull offers Invea Therapeutics Inc stock information, including NASDAQ: INAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAI stock methods without spending real money on the virtual paper trading platform.